With one in 10 Aussies over 65yo affected by Alzheimer’s, China is playing a lead role in finding the answers with Japanese drug company Eisai preparing to roll out its drug Leqembi to 1,500 people. Leqembi (aka Lecanemab) is not a cure – instead, it slows the disease’s progression giving people more time to live independently. It’s not yet approved for use in Oz, but is under consideration by the TGA… So far, only China, the US and Japan have given it the green light, but with millions of people suffering from the disease globally, the prospective market is huge making other drug companies keen to join the race. That includes America’s Eli Lilly which is developing a similar treatment called Donanemab, which it’s also trialling on 1,500 volunteers in China, Taiwan, South Korea and Europe.